Long-term burden of heart failure: a population-based cohort study on mortality and rehospitalizations Authors: Loreto Lancia, Angelo Dante, Valeria Caponnetto, Cristina Petrucci, Vittorio Masotta, Ilaria Paoli, Gianluca Azzellino, Leondino Mammarella, Silvio Romano Published: 2026 ABSTRACT AbstractHeart failure (HF) is a prevalent, progressive syndrome, and a leading cause of hospitalization, mortality, and healthcare expenditure worldwide, especially among older adults. This study aimed to assess the long-term burden of mortality, rehospitalizations and their composite among HF patients and to identify independent predictors of these outcomes. A population-based retrospective cohort study was conducted across all hospitals in the province of L’Aquila, Italy, including all residents discharged alive after an index HF hospitalization between 1 January 2014 and 31 December 2022, with follow-up through 31 December 2023. Kaplan–Meier analysis estimated event rates at 30 days, 90 days, 1 year, 5 years and 9 years. Predictors of the 5-year composite outcome (death or rehospitalization) and rehospitalization frequency were analyzed using multivariable Cox regression and negative binomial models. A total of 5,883 patients were included. By 5 years, 69.4% had experienced the composite outcome, increasing to 85.4% by 9 years. Nearly half of the rehospitalizations occurred in the first year. Older age, male sex, longer initial hospital stay, and earlier discharge year were associated with poorer outcomes. HF poses a long-term burden, highlighting the need for ongoing care, in which nurses are central to improve outcomes and care quality.Keywords: Heart failure, Long-term outcomes, Mortality, Nursing care, Population-based study, RehospitalizationSubject terms: Cardiology, Diseases, Health care, Medical research, Risk factors Introduction Heart failure (HF) is a progressive clinical syndrome arising from various cardiac disorders and remains one of the leading causes of hospitalization and mortality worldwide1. It affects over 64 million individuals globally and represents an escalating public health challenge in both developed and developing countries2. European observational data, such as those from the ESC-HF Pilot Survey, have underscored regional disparities in HF characteristics and outcomes across 12 countries3. In Western Europe, the prevalence of HF in the general population ranges from 1% to 2%, increasing markedly with age and exceeding 16% among individuals aged ≥ 74 years2,4. Despite notable advances in treatment, HF continues to be associated with substantial morbidity and mortality, particularly among older adults, individuals with multiple comorbidities and patients with reduced ejection fraction5. Hospitalization is a pivotal event in the course of HF, often indicating clinical decompensation and substantially elevating the risk of subsequent hospitalizations and death6. Recurrent hospitalizations not only impose significant physical and emotional burdens on patients and caregivers but also drive healthcare costs, accounting for more than 70% of the total expenditure related to HF care2. In Italy, HF ranks among the most common causes of hospital admission and contributes significantly to healthcare resource utilization. The cost of care for patients with HF is nearly double that of matched individuals without the condition7,8. Evidence from systematic reviews and meta-analyses has demonstrated that multidisciplinary HF management programmes—encompassing nurse-led clinics, home visits and telemonitoring—can reduce unplanned hospitalizations and improve survival9–12. Accordingly, the latest European Society of Cardiology (ESC) guidelines and their 2023 focused update strongly recommend implementing such programmes to optimize pharmacologic therapy, promote adherence, enhance patient education and facilitate early detection of clinical deterioration1,13. However, the adoption of these models remains inconsistent across Italian regions. Often confined to high-risk patients or specialized centres, these initiatives fail to reach the broader HF population14. This challenge is compounded by an underdeveloped community-based care infrastructure, a predominantly hospital-centred healthcare system15, the lack of formally defined clinical specialization pathways for nurses16 and widespread missed nursing care in home settings17. Although extensive research has been conducted, most studies focus on short-term outcomes, leaving a critical gap in knowledge regarding the long-term trajectory of HF—particularly mortality, readmission trends and their underlying predictors. A comprehensive understanding of these long-term patterns is essential to inform evidence-based strategies and minimize preventable hospitalizations. Methods Aim To address the described gaps, the AQUORE study (Italian study name) aimed to quantify the long-term burden of mortality, rehospitalizations and their composite among patients discharged alive following an index HF hospitalization. Specifically, this study investigated the incidence, timing and predictors of these adverse outcomes using population-based real-world data collected in a central Italian province from 2014 to 2023. Study design, setting and participants This retrospective, population-based cohort study utilized administrative data from all public and private hospitals within the province of L’Aquila, located in central Italy. The region has approximately 300,000 residents distributed across 5,035 km2. The study included all adult residents discharged alive after an index hospitalization for HF between 1 January 2014 and 31 December 2022. Follow-up extended through December 31, 2023. The index hospitalization was defined as the first recorded admission for HF during the study period, identified after a 4-year look-back period with no prior HF-related hospitalizations. This approach was adopted to approximate incident cases while minimizing the inclusion of patients with prior HF-related hospitalizations. HF was identified using the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes: HF (428.x), hypertensive heart disease with HF (402.01, 402.11, 402.91, 404.01, 404.03, 404.11, 404.13 and 404.91), cardiogenic shock (785.51), and rheumatic HF (398.91). Patients were followed for variable durations depending on the year of their index admission, ranging from a maximum of approximately 9 years (for admissions on 1 January 2014) to a minimum of 1 year (for those on 31 December 2022). Outcomes assessed included HF rehospitalizations, all-cause mortality and a composite endpoint defined as the first occurrence of either outcome. These were evaluated at fixed time intervals: 30 days, 90 days, 1 year, 5 years and 9 years. Variables, data sources and bias control Demographic and clinical data, including age, sex, marital status, length of stay during the index admission and HF-related diagnosis and Diagnosis-Related Group (DRG) classification, were extracted from the hospital discharge database (Scheda di Dimissione Ospedaliera SDO). Age was categorized into predefined groups (< 50, 50–74, 75–84, ≥ 85 years) for descriptive analyses and into three categories (< 75, 75–84, ≥ 85 years) for multivariable analyses. Marital status was categorized as single, married, separated/divorced, widowed, or not declared. Length of stay (LOS) was dichotomized (≤ 7 vs. >7 days). Mortality data were obtained from the national mortality registry. Records were linked using a unique anonymized patient identifier, ensuring complete longitudinal tracking at the individual level. To reduce the risk of misclassification bias, only admissions with a primary diagnosis of HF were considered. Variability in diagnostic coding practices was addressed by applying a validated set of ICD-9-CM codes widely used in epidemiological studies of HF18. Statistical analysis Descriptive statistics were used to summarize baseline demographic and clinical characteristics. Cumulative event rates for HF rehospitalizations, all-cause mortality and the composite endpoint were estimated using the Kaplan–Meier method at predefined intervals: 30 days, 90 days, 1 year, 5 years and 9 years. Median event-free survival times and corresponding 95% Confidence Intervals (95% CIs) were reported. The log-rank test was used to compare survival curves across subgroups defined by age, sex and calendar period. Multivariable Cox proportional hazards regression was employed to identify independent predictors of the 5-year composite outcome. Results were expressed as hazard ratios (HRs) with 95% CIs. To examine factors associated with the frequency of rehospitalizations within 5 years, a negative binomial regression model was applied. The logarithm of person-time was included as an offset to account for differences in follow-up duration. Results were reported as Incidence Rate Ratios (IRRs) with 95% Confidence Intervals. All statistical analyses were performed using IBM SPSS Statistics, version 27.0 (IBM Corp., Armonk, New York). Ethics approval and informed consent Ethical approval was granted by the Territorial Ethics Committee of the Abruzzo Region (C.Et.R.A.) on October 19, 2023 (RA 0342362). The requirement for informed consent for participation and publication was formally waived by the Ethics Committee due to the study’s retrospective design and the exclusive use of fully anonymized administrative data, in compliance with national regulations and the European General Data Protection Regulation (GDPR), Article 89. Results Study population Of the 6,461 patients who experienced an index hospitalization for HF between 1 January 2014 and 31 December 2022, a total of 5,883 (91.05%) were discharged alive and were followed for periods ranging from approximately 1 to 9 years. Outcomes assessed included HF rehospitalization, all-cause death and the composite endpoint (first occurrence of either event). Baseline characteristics are shown in Table 1. The median age at index hospitalization was 82 years (interquartile range IQR: 13) and was higher among females (83 vs. 79 years); females comprised 51.8% of the cohort. Over 80% of patients were aged ≥ 70 years. The most common discharge diagnoses were unspecified congestive HF (29.4%), left HF (22.2%), benign hypertensive heart disease with HF (14.4%) and unspecified HF (10.7%). The median length of stay was 8 days (IQR = 6). Marital status data were available for 71.5% of patients, of whom 42.5% were married and 16.5% were widowed. Table 1Annual distribution of patients discharged alive following an index hospitalization for heart failure, 2014–2022.Subjects5,883 Sex Male2,838 (48.2%)Female3,045 (51.8%) Marital status Single629 (10.7%)Married2,499 (42.5%)Separated49 (0.8%)Divorced54 (0.9%)Widow973 (16.5%)Not declared1,679 (28.5%) Age Mean (SD)79.28 (10.82)Median (IQR)82 (13) Age wide group < 5097 (1.6%)50–741,450 (24.6%)75–842,225 (37.8%)85+2,111 (35.9%) Diagnosis-Related Group 124280 (4.8%)1274,959 (84.3%)551242 (4.1%)Others402 (6.8%) ICD-9 principal diagnosis code 428.01,731 (29.4%)428.11,307 (22.2%)428.9630 (10.7%)402.11846 (14.4%)402.91182 (3.1%)428.20129 (2.2%)428.21281 (4.8%)428.23139 (2.4%)428.31110 (1.9%)Others528 (9.0%) Length of stay Mean (SD)10.81 (20.52)Median (IQR)8 (6)<= 7 days2,926 (49.7%)8 + days2,957 (50.3%) Annual distribution of patients discharged alive following an index hospitalization for heart failure, 2014–2022. Cumulative event rates over time Table 2 shows the cumulative incidence of HF rehospitalizations, all-cause mortality and the composite endpoint at 30 days, 90 days, 1 year, 5 years and 9 years, stratified by sex and age group (< 50, 50–74, 75–84, ≥ 85 years). Rehospitalization rates increased from 4.9% at 30 days to 38.3% at 9 years. All-cause mortality rose from 6.0% to 79.9%, and the composite endpoint from 10.2% to 85.4%. Table 2Cumulative incidence rates (%) of heart failure rehospitalization, all-cause mortality and composite outcomes at 30 days, 90 days, 1 year, 5 years and 9 years, stratified by sex and age group.Follow-upCohortAge groupDischarged aliveTotal ReadmissionsMale ReadmissionsFemale ReadmissionsTotal DeathsMale DeathsFemale DeathsTotal CompositeMale CompositeFemale Composite30 days2014–2022< 50972.1%3.1%00002.1%3.1%050–741,4504.0%4.3%3.5%2.0%1.9%2.1%5.8%6.1%5.2%75–842,2255.0%4.7%5.4%4.6%5.1%4.1%9.2%9.3%9.1%85+2,1115.5%4.6%6.1%10.5%10.7%10.3%14.7%14.2%15.0%Total5,8834.9%4.5%5.3%6.0%5.5%6.4%10.2%9.5%10.9%90 days2014–2022< 50973.1%3.1%3.1%0003.1%3.1%3.1%50–741,4507.4%8.1%6.1%5.0%4.5%6.0%11.6%11.9%10.9%75–842,2258.8%9.2%8.4%9.2%10.1%8.4%16.6%17.8%15.6%85+2,1119.4%8.8%9.8%20.0%19.6%20.2%26.2%25.9%26.4%Total5,8838.6%8.6%8.5%11.9%10.7%13.0%18.6%17.8%19.4%1 year2014–2022< 509711.3%12.3%9.4%2.1%06.2%11.3%12.3%9.4%50–741,45013.2%14.4%11.1%12.6%12.2%13.2%23.2%23.8%22.3%75–842,22517.5%17.9%17.2%19.6%21.7%17.7%32.3%34.4%30.4%85+2,11116.9%16.9%16.8%36.6%36.4%36.7%45.2%45.9%44.8%Total5,88316.1%16.4%15.9%23.7%22.2%25.1%34.3%33.6%35.0%5 years2014–2018< 505332.1%36.8%20.0%15.1%15.8%13.3%35.8%42.1%20.0%50–7479826.6%28.5%23.2%36.5%39.3%31.5%50.0%52.3%46.0%75–841,39634.1%33.0%35.1%58.1%62.4%54.4%69.6%71.4%68.1%85+1,29528.1%27.0%28.7%77.8%78.7%77.3%82.5%83.4%81.9%Total3,54230.2%30.0%30.3%59.8%58.9%60.6%69.4%68.3%70.4%9 years2014< 501127.3%25.0%33.3%27.3%25.0%33.3%36.4%37.5%33.3%50–7416436.6%37.0%35.9%57.9%58.0%57.8%71.3%71.0%71.9%75–8431343.1%42.6%43.5%82.4%88.5%78.5%87.5%91.0%85.3%85+24533.9%31.8%35.0%93.9%96.5%92.5%94.3%96.5%93.1%Total73338.3%37.5%39.0%79.9%79.4%80.4%85.4%84.8%85.9%30 days2014–2018Total3,5425.1%4.7%5.4%6.1%5.8%6.4%0.1%10.1%11.1%2019–2022Total2,3414.7%4.2%5.2%5.8%5.2%6.4%0.1%8.6%10.7%90 days2014–2018Total3,5429.4%9.5%9.3%12.5%11.6%13.2%0.2%19.3%20.0%2019–2022Total2,3417.3%7.4%7.3%11.0%9.4%12.6%0.2%15.6%18.4%1 year2014–2018Total3,54218.2%18.5%18.0%24.2%22.7%25.6%0.4%35.8%36.7%2019–2022Total2,34112.9%13.4%12.5%22.9%21.4%24.3%0.3%30.5%32.3% Cumulative incidence rates (%) of heart failure rehospitalization, all-cause mortality and composite outcomes at 30 days, 90 days, 1 year, 5 years and 9 years, stratified by sex and age group. Significant differences across age groups were observed in sex-stratified log-rank tests at most time points (p < 0.001), except for 30-day and 9-year rehospitalizations (p = 0.324 and 0.773, respectively). Event rates increased with both follow-up duration and age (Fig. 1). Cumulative rates of composite outcome (a), all-cause mortality (b), and heart failure rehospitalizations (c) over time, stratified by age group. Composite endpoint and rehospitalizations within 5 years At the 5-year follow-up, the median time to the composite endpoint was 783 days (95% CI = 724–842), primarily driven by mortality (Fig. 2A). This pattern persisted at 9 years (Fig. 2B). Kaplan–Meier curves showing the cumulative probability (1 - survival) of experiencing the first event (composite outcome, rehospitalization, or death) over time (in days) during 5-year (a) and 9-year (b) follow-up. Kaplan–Meier analyses stratified by age revealed that females had significantly better outcomes than males for all endpoints (log-rank p < 0.001). Among 3,542 patients discharged alive between 2014 and 2018 and followed for 5 years, 1,069 (30.2%) experienced ≥ 1 HF rehospitalization, accounting for 1,818 total events—an incidence rate of 16.74 events per 100 person-years. Nearly half (47.8%) of these rehospitalizations occurred within the first year post-discharge. Of all repeated hospitalizations, 40.9% were second or later episodes, and 16.9% were third or higher. Temporal trends in outcomes When comparing the 2014–2018 and 2019–2022 cohorts and stratifying by age, patients discharged in the more recent period had significantly better outcomes for the composite endpoint at 30 days, 90 days and 1 year (Log-rank p < 0.001 for all; Fig. 3). Comparative analysis of cumulative composite outcome rates (rehospitalization or all-cause mortality) at 30 days, 90 days and 1 year, stratified by age group and cohort period (2014–2018 vs. 2019–2022). Predictors of 5-year outcomes Multivariable Cox regression identified older age as the strongest independent predictor of the 5-year composite endpoint. Compared with patients aged < 75 years, those aged 75–84 had an HR of 1.78 (95% CI = 1.56–2.04), and those ≥ 85 had an HR of 2.56 (95% CI = 2.23–2.93). Other significant predictors included longer hospital stay (> 7 vs. ≤7 days): HR = 1.27 (95% CI = 1.16–1.40), male sex: HR = 1.15 (95% CI = 1.04–1.26), and earlier year of discharge (2014 vs. 2018): HR = 1.20 (95% CI = 1.02–1.40). Marital status was not significantly associated with the composite outcome, although single individuals had marginally worse outcomes than married ones (HR = 1.09; 95% CI = 0.99–1.21; Fig. 4A). Multivariable-adjusted predictors of the 5-year composite outcome (a) and rehospitalization (b). LOS: length of stay. Multivariable negative binomial regression for repeated rehospitalizations showed that older age, longer length of stay and earlier discharge year were significant predictors, while sex and marital status were not significantly associated with the outcome (Fig. 4B). Discussion This population-based study offers a comprehensive overview of long-term outcomes among patients discharged alive after an index hospitalization for HF. We found a substantial and progressively increasing burden of adverse events over time. At 5 years, nearly 70% of patients had experienced the composite outcome of HF rehospitalization or death, rising to 85.4% at 9 years. The incidence of repeated HF-related hospitalizations reached 16.7 per 100 person-years, with almost half occurring within the first year after discharge. Heart failure remains a major public health concern across Western countries19. In Italy, the decentralized healthcare system, absence of a national HF registry and predominant reliance on hospital-based care15,20 highlight the importance of using hospital discharge records for surveillance and planning. According to national data, DRG 127 (Heart Failure & Shock) ranks as the third most frequent disease-related cause of hospitalization in Italy, with over 123,000 admissions in 2022 alone, totalling more than 1.2 million inpatient days and generating annual costs exceeding €374 million7. However, our findings suggest that this figure may underestimate the true burden of HF, as DRG 127 does not capture all HF cases identified through ICD-9-CM codes. The demographic characteristics of our study population—particularly age and sex distribution—were consistent with national statistics, reinforcing the representativeness of our data and its potential to inform regional and national health strategies. However, the lack of external validation may limit the generalizability of these findings. Encouragingly, outcomes have improved over time: patients discharged in more recent years exhibited significantly lower risks for the composite outcome, potentially reflecting enhanced continuity of care and broader implementation of evidence-based therapies, aligned with updated clinical guidelines1,13. The observed improvement in outcomes over time should be interpreted cautiously. While it may reflect a progressive implementation of guideline-directed medical therapies and improvements in care pathways, it may also be influenced by changes in admission thresholds and healthcare organization over the study period, rather than being solely attributable to advances in pharmacological treatment. Older age consistently emerged as the strongest independent predictor of both the composite outcome and repeated hospitalizations, consistent with findings from prior studies2,5,21. Longer hospital stay (> 7 days) at index admission was also independently associated with poorer outcomes, likely reflecting greater disease severity or more complex care needs. Social factors may influence outcomes22. In our analysis, patients living alone showed a tendency toward worse prognoses compared with married individuals, although this association did not reach statistical significance in multivariable models. These findings nonetheless highlight the importance of identifying and addressing social vulnerabilities through multidisciplinary care strategies. Nurses, due to their close contact with patients and communities, are uniquely positioned to coordinate care and deliver personalized support interventions14,23,24. Our results align with those of other Italian population-based studies, which reported similar demographic characteristics and comparable 1-year mortality rates (ranging from 19% to 24%)21,25,26. Rehospitalization rates were also consistent, though some studies reported slightly higher values in older populations or when considering all-cause readmissions. These differences may reflect changes over time in care delivery, data completeness, and the availability of new therapeutic options. Internationally, our findings are consistent with global reports on HF epidemiology2,4,5. Despite advances in therapy, HF continues to be associated with high morbidity and mortality. Previous studies have reported 1-year post-discharge mortality rates between 20% and 30%, and all-cause readmission rates of 35%–50%—figures comparable with our 1-year mortality estimate of 23.7% and 5-yearHF-specific rehospitalization rate of 30.2%. These parallels reinforce the external validity of our findings. While improvements in mortality have been observed over time, the persistent burden of rehospitalizations underscores the need for more effective post-discharge strategies and comprehensive long-term management. HF management programmes have proven effective in improving patient outcomes and should be integral to long-term care. These programmes typically include structured discharge planning, nurse-led clinics, home-based care, remote monitoring and individualized long-term follow-up. Community-based HF clinics, in collaboration with primary care, are well-suited for managing stable patients, while hospital-based services can support those who are clinically unstable or severely ill14. Within both settings, nurses play a central role in managing comorbidities, recognizing early signs of clinical deterioration and promoting patient self-care. Their responsibilities extend to enhancing medication adherence, supporting symptom monitoring and encouraging therapeutic lifestyle behaviours. Moreover, they are instrumental in engaging and empowering family caregivers, whose involvement is vital to successful patient self-management27,28. However, several limitations should be considered when interpreting our results. First, the use of routinely collected hospital discharge data limited access to detailed clinical information such as left ventricular ejection fraction, laboratory results, or pharmacological treatments. Consequently, we could not stratify patients by HF phenotype or disease severity, both of which could influence prognosis. Second, although we applied a 4-year look-back period to identify index hospitalizations, this may not have been sufficient to completely exclude patients with a prior HF history, particularly those admitted in the early study years. This limitation could have led to an overestimation of incident cases during that period. However, as our primary aim was to assess long-term outcomes rather than incidence rates, the impact of this limitation on our key findings is likely minimal. Additionally, important variables such as socioeconomic status, cognitive function and caregiver support were unavailable in the dataset. These unmeasured factors may influence both clinical outcomes and the likelihood of rehospitalization, thereby limiting the comprehensiveness of our predictive models. Finally, while mortality data were obtained from national registries, we could not distinguish between in-hospital and out-of-hospital deaths, nor assess cause-specific mortality. Conclusions This population-based study demonstrates that, despite recent improvements in outcomes, HF continues to be associated with substantial mortality and rehospitalization rates, particularly within the first year following hospital discharge. The 5-year outcomes were significantly influenced by patient age, sex and the length of the index hospitalization. Temporal improvements observed over the study period underscore the importance of implementing effective post-discharge strategies and comprehensive long-term HF management protocols. Nurses are positioned to play a pivotal role not only in delivering direct clinical care but also in facilitating patient self-management, supporting caregivers, coordinating follow-up care and addressing the broader educational and psychosocial needs of patients with HF. Abbreviations 95% Confidence Intervals Diagnosis-Related Group European Society of Cardiology Heart failure International Classification of Diseases, Ninth Revision, Clinical Modification Interquartile range Incidence Rate Ratio Author contributions L.L. conceived the study, designed the methodology, performed the investigation and data curation, conducted formal analysis and validation, created visualizations, managed resources, supervised the project, and wrote both the original draft and revisions. A.D., C.P., and S.R. contributed to the conceptualization, methodology development, investigation, supervision, and writing – review and editing. V.C. contributed to methodology, data curation, and writing – review and editing. V.M. contributed to methodology, investigation, data curation, and writing – review and editing. I.P. and G.A. contributed to data curation and writing – review and editing. L.M. contributed to conceptualization, methodology, investigation, data curation, validation, visualization, supervision, and writing – review and editing. All authors approved the final version of the manuscript. Funding This study was funded by the Department of Life, Health and Environmental Sciences at the University of L’Aquila. The Department was not involved in the study design, data collection, analysis or interpretation, manuscript writing, or the decision to submit the article for publication. Data availability The data generated and analysed during the study are not publicly available due to confidentiality concerns related to patient information. However, anonymized datasets may be available upon reasonable request. Declarations Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement The data generated and analysed during the study are not publicly available due to confidentiality concerns related to patient information. However, anonymized datasets may be available upon reasonable request.